Trend of A-share and Hong Kong stock innovative drug sector this week
In the first week of March 2022, a total of 12 stocks in the innovative drug sector in mainland and Hong Kong rose and 40 stocks fell. Among them, the top three gainers are Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (+ 6.25%), Maiwei bio-u (+ 5.78%), Geli pharmaceutical-b (+ 4.55%). The top three declines were zaiding pharmaceutical-sb (- 23.82%), gakos-b (- 17.89%), and Hehuang Pharmaceutical (- 16.43%). This week, the A-share innovative drug sector fell 0.22%, outperforming the CSI 300 index by 1.68pp, and biomedicine fell 1.03%. In the past six months, A-share innovative drugs have fallen by 11.37%, underperforming the Shanghai and Shenzhen 300 index by 7.1pp, and biomedicine has fallen by 24.29%. This week, the innovative drug sector of Hong Kong stocks fell 11.45%, underperforming the Hang Seng Index by 3.79pp, and Hang Seng healthcare fell 6.21%. Over the past six months, innovative drugs in Hong Kong stocks have fallen by 25.43%, underperforming the Hang Seng Index by 9.81pp, and Hang Seng health care has fallen by 33.39%.
Progress of key innovative drugs in China
In March, a new drug was approved for marketing in China. One drug was approved for sale in China this week. Nmpa approved montmorillonite of yipusheng for the treatment of diarrhea.
Progress of overseas key innovative drugs
In March, no new drug was approved by FDA. Three new drugs were approved this week. The new molecular entity pacitinib of CTI biopharma Corp was approved for listing on February 28 for bone marrow fibrosis. Kaleo Inc’s naloxone hydrochloride new formula / new manufacturer was approved for marketing on February 28. The new ranolazine dosage form of sun Pharma global was approved for marketing on February 28 to stabilize angina pectoris.
This week’s small topic – research and development progress of JAK inhibitors
There are 154 JAK inhibitors on the global market & under development, of which 10 have been listed, 1 has applied for listing, 7 in phase III, 3 in phase II / III, 28 in phase II, 6 in phase I / II, 39 in phase I and ind2. There are 55 listed & under research in China, of which 4 have been listed (Lilly, Alberta, Pfizer and Novartis), 1 has applied for listing (Pfizer), 6 are in phase III clinical (Sanofi, anstelai, Bristol Myers Squibb, Ruishi biology, Pfizer, Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) ), 1 is in phase II / III clinical, 8 is in phase II clinical, 2 is in phase I / II clinical, 12 is in phase I clinical and 5 is inds. Among the listed JAK inhibitors, tofatib has the most approved indications, including ankylosing spondylitis, juvenile idiopathic arthritis, ulcerative colitis, psoriatic arthritis and rheumatoid arthritis. In 2021, the sales of tofatib reached US $2455 million (+ 0.7%), and the approval of a number of indications promoted the rapid growth of tofatib since its launch in 2012.
Progress of global key innovative drug transactions this week
A total of 12 key transactions were disclosed this week. Companies involved include Tianyan pharmaceutical and Sanofi, Yifan Pharmaceutical Co.Ltd(002019) and apogepha arzneimittel, proteovant therapeutics and blueprint medicines, Huadong Medicine Co.Ltd(000963) and Heidelberg Pharma, biohaven pharmaceuticals and Knopp biosciences.
Risk warning: drug price reduction risk; The implementation progress of medical reform policy is lower than the expected risk; Risk of R & D failure.
